BACKGROUND: Imatinib, a competitive inhibitor of BCR-ABL tyrosine kinase, is now the first-line treatment for chronic myelogenous leukemia (CML). Therapeutic drug monitoring targeting trough plasma levels of about 1000ng/mL may help to optimize the therapeutic effect. METHODS: We developed a high-performance liquid chromatography (HPLC) method with UV/Diode Array Detection (DAD) for trough imatinib concentration determination in human plasma. Imatinib trough levels were measured in plasma from 65 CML patients using our method and LC-MS/MS as the reference method. Results with these two methods were compared using Deming regression, chi-square test, and sign test. RESULTS: The calibration curve was prepared in blank human plasma. HPLC-UV/DAD calibration curves were linear from 80 to 4000ng/mL, and the limit of quantification was set at 80ng/mL. The between-day variation was 6.1% with greater than 96% recovery after direct plasma deproteinization and greater than 98% recovery from the column. No significant differences in imatinib plasma levels were found between HPLC-UV/DAD and LC-MS/MS. CONCLUSIONS: This HPLC-UV/DAD method was sufficiently specific and sensitive for imatinib TDM, with no evidence of interference. Our rapid inexpensive HPLC-UV/DAD method that requires only widely available equipment performs well for plasma imatinib assays. Copyright 2009 Elsevier B.V. All rights reserved.
BACKGROUND:Imatinib, a competitive inhibitor of BCR-ABL tyrosine kinase, is now the first-line treatment for chronic myelogenous leukemia (CML). Therapeutic drug monitoring targeting trough plasma levels of about 1000ng/mL may help to optimize the therapeutic effect. METHODS: We developed a high-performance liquid chromatography (HPLC) method with UV/Diode Array Detection (DAD) for trough imatinib concentration determination in human plasma. Imatinib trough levels were measured in plasma from 65 CMLpatients using our method and LC-MS/MS as the reference method. Results with these two methods were compared using Deming regression, chi-square test, and sign test. RESULTS: The calibration curve was prepared in blank human plasma. HPLC-UV/DAD calibration curves were linear from 80 to 4000ng/mL, and the limit of quantification was set at 80ng/mL. The between-day variation was 6.1% with greater than 96% recovery after direct plasma deproteinization and greater than 98% recovery from the column. No significant differences in imatinib plasma levels were found between HPLC-UV/DAD and LC-MS/MS. CONCLUSIONS: This HPLC-UV/DAD method was sufficiently specific and sensitive for imatinib TDM, with no evidence of interference. Our rapid inexpensive HPLC-UV/DAD method that requires only widely available equipment performs well for plasma imatinib assays. Copyright 2009 Elsevier B.V. All rights reserved.
Authors: Emil Vinţeler; Nicoleta-Florina Stan; Raluca Luchian; Călin Căinap; João P Prates Ramalho; Vasile Chiş Journal: J Mol Model Date: 2015-03-13 Impact factor: 1.810
Authors: Stéphane Prost; Francis Relouzat; Marc Spentchian; Yasmine Ouzegdouh; Joseph Saliba; Gérald Massonnet; Jean-Paul Beressi; Els Verhoeyen; Victoria Raggueneau; Benjamin Maneglier; Sylvie Castaigne; Christine Chomienne; Stany Chrétien; Philippe Rousselot; Philippe Leboulch Journal: Nature Date: 2015-09-02 Impact factor: 49.962
Authors: Jessica N Rabuck; Suk-Joon Hyung; Kristin S Ko; Christel C Fox; Matthew B Soellner; Brandon T Ruotolo Journal: Anal Chem Date: 2013-07-23 Impact factor: 6.986
Authors: Vinícius Marcondes Rezende; Ariane Julio Rivellis; Melissa Medrano Gomes; Felipe Augusto Dörr; Mafalda Megumi Yoshinaga Novaes; Luciana Nardinelli; Ariel Lais de Lima Costa; Dalton de Alencar Fisher Chamone; Israel Bendit Journal: Rev Bras Hematol Hemoter Date: 2013